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Abstract
Voriconazole has been associated with cutaneous squamous cell carcinoma (cSCC) in transplant patients but less is known about
the risk in less severely immunosuppressed patients. Our aim was to estimate the incidence of cSCC after voriconazole exposure
in patients with chronic pulmonary aspergillosis on a background of chronic lung disease. The notes of patients seen at a tertiary
referral centre from 2009 to 2019 with chronic pulmonary aspergillosis were reviewed for the diagnosis of cSCC and
voriconazole use documented. Among 1111 patients, 668 (60.1%) received voriconazole for longer than 28 days. Twelve
patients received a diagnosis of cSCC; nine had used voriconazole. Mean duration of voriconazole use was 36.7 months. The
crude incidence rate was 4.88 in 1000 person/years in those who had voriconazole and 2.79 in 1000 patient/years in those who
did not receive voriconazole for longer than 28 days. On Cox regression, age (HR 1.09, 95% CI 1.02–1.16, p = 0.01) and male
gender (HR 3.97, 95% CI 0.84–18.90, p = 0.082) were associated with cSCC. Voriconazole use was associated with a slightly
increased risk, which was not significant (HR 1.35, 95% CI 0.35–5.20, p = 0.659). Voriconazole use beyond 28 days did not lead
to a significantly increased risk of cSCC in a large cohort of patients with chronic pulmonary aspergillosis.
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Introduction
The spectrum of disease caused by Aspergillus encompasses
allergic, chronic, saprophytic and invasive disease, depending
on the degree of host immunosuppression. Chronic pulmo-
nary aspergillosis (CPA) affects immunocompetent or mildly
immunosuppressed patients with chronic lung disease, such as
COPD, bronchiectasis, prior pulmonary TB or sarcoidosis
(Smith and Denning 2011). Voriconazole is one of the first-
line agents in CPA and is often used long-term. Guidelines
suggest at least six months of treatment; however, in practice it
may be used for longer durations, often for years, as response
may be delayed and relapses are common (Denning et al.
2016).
Long-term voriconazole treatment is associated with hepa-
totoxicity, neurotoxicity, photosensitivity and, importantly, a
risk of skin cancer. Photosensitivity is common and there is a
clear association between its emergence and subsequent de-
velopment of skin cancer (Cowen et al. 2010). It is
hypothesised that voriconazole N-oxide, the primary metabo-
lite of voriconazole and a UVB biproduct, potentiates UVA-
mediated oxidative DNA damage or inhibits DNA repair (Ona
and Oh 2015). Photosensitivity tends to resolve after cessation
of the drug; it is not known if this is true of the skin cancer risk.
The association between voriconazole and cutaneous ma-
lignancy, particularly cutaneous squamous cell carcinoma
(cSCC), is well established in severely immunocompromised
patients like haematopoietic stem cell transplant (HSCT) or
lung transplant recipients, with case reports in patients with
renal transplant or HIV (Brunel et al. 2008; Hamandi et al.
2018; Kolaitis et al. 2017; Vanacker et al. 2008; Wojenski
et al. 2015). These patients are already at increased risk of
non-melanoma skin cancer and voriconazole was shown to
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increase this risk. Therefore, long-term voriconazole use
should be pursued only if the benefit outweighs the risk, and
only if frequent skin inspection is possible.
Whereas extensive data are available for the risk in the
severely immunocompromised patients, the incidence, risk
factors and clinical presentation of cSCC in other patient
groups treated with voriconazole is not well described. At
the National Aspergillosis Centre (NAC), more than 120 pa-
tients with CPA are seen yearly and a substantial number will
be treated with voriconazole as first-line or salvage therapy,
often for longer than 6 months. This large cohort of patients
can provide valuable insights into the risk of cSCC in a pop-
ulation other than transplant recipients. The aim of this study
was to estimate the incidence of cSCC after voriconazole ex-
posure in a population without severe immune compromise.
Methods
All patients with the diagnosis of CPA referred to the NAC
(2009–March 2019) were included retrospectively. The start
of observation was taken as the day voriconazole was started
for patients who received voriconazole, and the first atten-
dance in clinic for patients who did not receive voriconazole.
Information was obtained from the medical notes for all sub-
sequent visits until March 2019 unless the patient was
discharged, lost to follow-up or died, in which case the last
observation point was the last clinic visit for patients who did
not develop cSCC and the time of diagnosis of cSCC in those
who did. Voriconazole exposure was documented as a binary
variable; patients receiving voriconazole for less than 28 days
were considered non-exposed. We used this cut-off based on
the practice to prescribe voriconazole for 28 days initially (as
patients have chronic rather than acute disease, and are seen in
the outpatient setting). Dosing and frequency of administra-
tion were not collected. Age, sex, underlying diseases, photo-
sensitivity, mean of the last five voriconazole levels, location
of cSCC, treatment and outcome were recorded for all patients
with cSCC. The crude incidence rate and age-specific inci-
dence rate of cSCC in patients who received voriconazole
were calculated. Cox regression was performed to compare
incidence of cSCC; parameters included were voriconazole
use, gender and age.
Results
A total of 1199 patients with the diagnosis of CPA were iden-
tified. Fifty-five had only one attendance with no follow-up
and were excluded. For 32 there was no clinical information.
One patient had been diagnosed with cSCC after having re-
ceived voriconazole before referral to NAC and was excluded
from further analysis. Of the 1111 patients with follow-up,
668 received voriconazole for 28 days or longer, 120 received
voriconazole for less than 28 days and 302 never received
voriconazole. Mean age was 66.6 years (range 21–96).
Female were 475 (42.8%). Mean follow-up duration was
29.3 months (IQR 35.0) for patients who did not have
voriconazole and 33.1 months (IQR 42.0) for those who had
voriconazole. There were 12 cases of cSCC; nine in patients
who received more than 28 days of voriconazole prior to can-
cer diagnosis (Table 1). All patients were white. All nine pa-
tients developed photosensitivity prior to cSCC diagnosis.
The mean duration of voriconazole therapy was 36.7 months
and the mean time from the start of therapy to cancer diagnosis
was 47.2 months. The mean age of patients with cSCC was
65.6 years (SD 12.1) and 10 (83.3%) were male. All were
white.
The crude incidence rate was 4.88 per 1000 person/years in
patients who received voriconazole for longer than 28 days
and 2.79 per 1000 person/years in patients who did not receive
voriconazole for longer than 28 days. Age-adjusted incidence
rates on voriconazole were 13.3 per 1000 person/years in
those aged > 74, 5.24 per 1000 person/years in those aged
65–74 and 2.33 per 1000 person/years on those younger than
65. On Cox regression, age (p = 0.01, HR 1.09, 95% CI 1.02–
1.16) was significantly associated with risk of cSCC. Male
gender (p = 0.082, HR 3.97, 95% CI 0.84–18.90) and
voriconazole use (p = 0.659, HR 1.35, 95% CI 0.35–5.20)
were associated with an increased risk of cSCC but did not
reach statistical significance. A Kaplan-Meier curve of cSCC
risk according to voriconazole status is presented in Fig. 1.
Discussion
This is the first study, to our knowledge, to estimate the inci-
dence of cSCC in a patient cohort on long-term voriconazole
other than HSCT or solid organ transplant recipients. We
found a slightly increased risk, although not significantly, of
cSCC in patients with CPA treated with voriconazole. Patients
with CPA usually have minimal or no immunosuppression;
therefore, their risk of skin cancer should be comparable with
that of the general population. The number of cases of cSCC
observed in this cohort suggests that voriconazole may in-
crease the risk of this cancer in patients without HSCT or solid
organ transplant. Half of the patients who developed cSCC
had some form of immune compromise, ranging from mild
(e.g. 5 mg of prednisolone) to more extensive (e.g. previous
chemotherapy for lung cancer). Therefore, it is possible that
the risk of cSCCwith voriconazole may be increased with any
form of immunosuppression, not only the profound immuno-
suppression associated with transplant.
The increased cSCC rate we observed may not be entirely
due to voriconazole, and could be attributed to our patients’
demographics, too, as CPA mainly affects middle-aged to
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elderly males, who have a higher incidence of cSCC
(Brewster et al. 2007). All patients who developed cSCC after
voriconazole use for longer than 28 days were male. cSCC is
more common in males, and we observed a striking predom-
inance of males in this series. In addition, chronic inflamma-
tion observed in CPA may be another factor predisposing to
cancer. Although we did not compare voriconazole levels
with those in patients who did not develop cSCC, the mean
voriconazole levels were within recommended limits in pa-
tients who developed cSCC, suggesting that therapeutic level
monitoring is not an effective way to prevent cancer
development.
cSCC was diagnosed several years after voriconazole ini-
tiation in all but one patient, and in no patient was the diag-
nosis made within 6 months of treatment. This supports the
recommendation that voriconazole use for up to 6 months is
considered acceptable regarding the malignancy risk. Only
one patient (case 8) developed cancer several years after
voriconazole was stopped. This suggests that the risk of ma-
lignancy is reduced soon after voriconazole is stopped. For the
















Type of cSCC and
location
Outcome
1 49, M Sarcoidosis on
prednisolone 5 mg







2 69, M Metastatic hepatocellular
carcinoma on sorafenib
Asthma





Resected with local flap. 2
new scalp SCCs 10 m later,
resected. New lesions 20 m
later, awaiting biopsy, died
from unrelated cause
4.19
3 69, M Sarcoidosis on
prednisolone 5 mg/day
4 y 7 m (with 3 m
interruption)
4 y 7 m 8 m into
therapy
Scalp Resected. No relapse
1.74







5 81, M Bronchiectasis 3y 4 m 3y 4 m 1 y into
therapy
Left ear Resected. 2 further SCCs of








Resected. Recurrence 6 m
later, resected. SCC on right
temple 12 m later, resected
0.93








8 77, M Previous TB
Right upper lobectomy












10 85, M COPD
Bronchiectasis
16 days 6 y 7 m None Scalp Resected. Second SCC 6 m
later, resected. Third SCC
18 m later, resected
11 78, F COPD
Prednisolone 10 mg
6 days 4 y 11 m None Left calf Resected, required skin graft
12 75, F ABPA
Bronchiectasis




aMean of last five measurements of voriconazole levels before cSCC diagnosis. Levels recorded only for patients for whom voriconazole use had a
temporal association with cSCC development. y, years; m, months; M, male; F, female
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three patients who were treated for only a few days (cases 10–
12), cSCC developed several years later; therefore, the asso-
ciation with voriconazole is dubious. In addition,
voriconazole-related cSCC described in case reports is multi-
focal and more aggressive (Vanacker et al. 2008). In our case
series, three patients had relapses and one required reconstruc-
tion surgery due to extensive disease. Overall, we did not
observe a particularly aggressive nature of disease.
This study has several limitations. The small number of
cSCC cases limits the accuracy of our incidence estimation.
We documented voriconazole use as a binary variable and did
not correlate duration of treatment with cancer risk. We as-
sumed a duration of less than 28 days as an arbitrary cut-off
for long-term voriconazole exposure. This is similar to what
was used by Hamandi et al. Using a different cut-off would
not have significantly altered the results, as most patients who
developed cSCC had either several months or only a few days
of treatment (Table 1). In addition, we did not document daily
or cumulative doses. The diagnosis of cSCC was done by
retrospective review of notes, and therefore some information
may have beenmissing. It is possible that some cases were not
recorded by the clinician. Voriconazole use may have led to a
more thorough assessment to rule out cancer compared with
patients not on voriconazole. Finally, it was not possible to
ascertain risk factors such as skin type or sun exposure, as
these are not recorded routinely in notes.
In summary, in a cohort of patients with CPA, long-term
voriconazole use was not associated with a significantly in-
creased risk of cSCC to an extent previously seen in severely
immunocompromised patients such as transplant recipients.
However, the incidence was higher compared with non-
exposed patients. In addition to counselling on the importance
of using high factor sunscreen and avoiding sun exposure,
regular monitoring for skin toxicity should be undertaken in
all patients on voriconazole for longer than six months, par-
ticularly when photosensitivity is an issue.
Authors’ contribution statement Chris Kosmidis conceived project and
wrote manuscript, Anna Mackenzie analysed data and wrote manuscript,
Chris Harris collected data and revised manuscript, Rola Hashad analysed
data and revised manuscript, Fiona Lynch collected data and revised
manuscript, David Denning analysed data and revised manuscript.
Data availability Not applicable.
Compliance with ethical standards
Conflict of interest Chris Kosmidis, Anna Mackenzie, Rola Hashad,
Chris Harris and Fiona Lynch report no conflicts of interest. DW
Denning and family hold Founder shares in F2G Ltd., a University of
Manchester spin-out antifungal discovery company. He acts or has re-
cently acted as a consultant to Scynexis, Pulmatrix, Zambon, iCo
Therapeutics, Roivant, Biosergen and Fujifilm. In the last 3 years, he
has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck,
Mylan and Pfizer. He is a longstanding member of the Infectious Disease
Society of America Aspergillosis Guidelines group, the European Society
for Clinical Microbiology and Infectious Diseases Aspergillosis
Guidelines group and the British Society for Medical Mycology
Standards of Care committee.
Ethics approval This study was a retrospective service evaluation and
ethical approval was not required, according to UK Health Research
Authority guidelines. The study was registered with the audit department
of Manchester University NHS Foundation Trust (Audit No. 8056).
Fig. 1 Kaplan-Meier curve of risk of developing cSCC (cutaneous squamous cell carcinoma) according to voriconazole status in patients with chronic
pulmonary aspergillosis
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